Toward understanding the essence of post-translational modifications for the Mycobacterium tuberculosis immunoproteome

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages 1-10

  van Els, Cécile A C M ^a   Corbière, Véronique ^b   Smits, Kaat ^b   van Gaans van den Brink, Jacqueline A M ^a   Poelen, Martien C M ^a   Mascart, Francoise ^b,c   Meiring, Hugo D ^d   Locht, Camille ^e,f  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d Institute for Translational Vaccinology ^*  (Netherlands)

^e INSERM U1019   (France)

^f UNIV LILLE   (France)

Author keywords

CD4CT cell epitope; Immunoproteome; MHC ligands; Mycobacterium tuberculosis; Post translational modification; Proteomics; T cell epitope repertoire

Indexed keywords

BCG VACCINE; FORMYLMETHIONINE; PEPTIDE DEFORMYLASE; PROTEIN KINASE;

ACETYLATION; ARTICLE; CELL COMPARTMENTALIZATION; DEAMINATION; GLYCOSYLATION; IMMUNE RESPONSE; IMMUNIZATION; LIPOGENESIS; METHYLATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

EID: 84928980875     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00361     Document Type: Article

References (132)

1. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol (2001) 19:93-129. doi:10.1146/annurev.immunol.19.1.93
2. Kaufmann SH. Howcan immunology contribute to the control of tuberculosis? Nat Rev Immunol (2001) 1:20-30. doi:10.1038/35095558
3. Blythe MJ, Zhang Q, Vaughan K, de Castro R Jr, Salimi N, Bui HH, et al. An analysis of the epitope knowledge related to mycobacteria. Immunome Res (2007) 3:10. doi:10.1186/1745-7580-3-10
4. Kunnath-Velayudhan S, Porcelli SA. Recent advances in defining the immuno-proteome of Mycobacterium tuberculosis. Front Immunol (2013) 4:335. doi:10. 3389/fimmu.2013.00335
5. Lindestam Arlehamn CS, Gerasimova A, Mele F, Henderson R, Swann J, Greenbaum JA, et al. Memory T cells in latent Mycobacterium tuberculo-sis infection are directed against three antigenic islands and largely con-tained in a CXCR3+CCR6+ Th1 subset. PLo S Pathog (2013) 9:e1003130. doi:10.1371/journal.ppat.1003130
6. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M. The immunological footprint of Mycobacterium tuberculosis T-cell epitope recog-nition. J Infect Dis (2012) 205(Suppl 2):S301-15. doi:10.1093/infdis/jis198
7. Cala-De Paepe D, Layre E, Giacometti G, Garcia-Alles LF, Mori L, Hanau D, et al. Deciphering the role of CD1e protein in mycobacterial phosphatidyl-myo-inositolmannosides (PIM) processing for presentation byCD1b toT lym-phocytes. J Biol Chem (2012) 287:31494-502. doi:10.1074/jbc.M112.386300
8. Gilleron M, Stenger S, Mazorra Z, Wittke F, Mariotti S, Bohmer G, et al. Dia-cylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. J Exp Med (2004) 199:649-59. doi:10.1084/jem.20031097
9. Layre E, Collmann A, Bastian M, Mariotti S, Czaplicki J, Prandi J, et al. Mycolic acids constitute a scaffold formycobacterial lipid antigens stimulating CD1-restricted T cells. Chem Biol (2009) 16:82-92. doi:10.1016/j.chembiol. 2008.11.008
10. Bastian M, Braun T, Bruns H, Rollinghoff M, Stenger S. Mycobacterial lipopeptides elicitCD4+CTLs inMycobacteriumtuberculosis-infected humans. J Immunol (2008) 180:3436-46. doi:10.4049/jimmunol.180.5.3436
11. Kasmar AG, Van Rhijn I, Magalhaes KG, Young DC, Cheng TY, Turner MT, et al. Cutting edge: CD1a tetramers and dextramers identify human lipopeptide-specific T cells ex vivo. J Immunol (2013) 191:4499-503. doi:10. 4049/jimmunol.1301660
12. Seshadri C, Turner MT, Lewinsohn DM, Moody DB, Van Rhijn I. Lipoproteins are major targets of the polyclonal human T cell response to Mycobacterium tuberculosis. J Immunol (2013) 190:278-84. doi:10.4049/jimmunol.1201667
13. Joosten SA, van Meijgaarden KE, vanWeeren PC, Kazi F, Geluk A, Savage ND, et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLo S Pathog (2010) 6:e1000782. doi:10.1371/journal.ppat.1000782
14. Heinzel AS, Grotzke JE, Lines RA, Lewinsohn DA, Mc Nabb AL, Streblow DN, et al. presentation of Mtb-derived antigen to human CD8+ T cells. J Exp Med (2002) 196:1473-81. doi:10.1084/jem.20020609
15. Mir SA, Sharma S. Role of MHC class Ib molecule, H2-M3 in host immunity against tuberculosis. Vaccine (2013) 31:3818-25. doi:10.1016/j.vaccine.2013. 04.005
16. Rodgers JR, Cook RG. MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol (2005) 5:459-71. doi:10.1038/nri1635
17. Adams EJ. Lipid presentation by human CD1 molecules and the diverse T cell populations that respond to them. Curr Opin Immunol (2014) 26C:1-6. doi:10.1016/j.coi.2013.09.005
18. Moody DB. The surprising diversity of lipid antigens for CD1-restricted T cells. Adv Immunol (2006) 89:87-139. doi:10.1016/S0065-2776(05)89003-0
19. Zajonc DM, Crispin MD, Bowden TA, Young DC, Cheng TY, Hu J, et al. Mol-ecular mechanism of lipopeptide presentation by CD1a. Immunity (2005) 22:209-19. doi:10.1016/j.immuni.2004.12.009
20. Mc Shane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med (2004) 10:1240-4. doi:10.1038/nm1128
21. Mustafa AS, Al-Attiyah R, Hanif SN, Shaban FA. Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells. Clin Vaccine Immunol (2008) 15:916-24. doi:10.1128/CVI. 00056-08
22. Skjot RL, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff TH, et al. Epi-tope mapping of the immunodominant antigen TB10.4 and the two homol-ogous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun (2002) 70:5446-53. doi:10.1128/IAI.70.10.5446-5453.2002
23. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, Verscheure V, et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLo SOne (2007) 2:e926. doi:10.1371/journal.pone. 0000926
24. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 181:7948-57. doi:10. 4049/jimmunol.181.11.7948
25. Vordermeier HM, Hewinson RG, Wilkinson RJ, Wilkinson KA, Gideon HP, Young DB, et al. Conserved immune recognition hierarchy of mycobacterial PE/PPE proteins during infection in natural hosts. PLo S One (2012) 7:e40890. doi:10.1371/journal.pone.0040890
26. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, Kremer K, et al. Human T cell epitopes of Mycobacteriumtuberculosis are evolutionarily hyper-conserved. Nat Genet (2010) 42:498-503. doi:10.1038/ng.590
27. Mc Evoy CR, Cloete R, Muller B, Schurch AC, van Helden PD, Gagneux S, et al. Comparative analysis of Mycobacterium tuberculosis pe and ppe genes reveals high sequence variation and an apparent absence of selective constraints. PLo S One (2012) 7:e30593. doi:10.1371/journal.pone.0030593
28. Uplekar S, Heym B, Friocourt V, Rougemont J, Cole ST. Comparative genomics of Esx genes from clinical isolates of Mycobacterium tuberculosis provides evidence for gene conversion and epitope variation. Infect Immun (2011) 79:4042-9. doi:10.1128/IAI.05344-11
29. Axelsson-Robertson R, Loxton AG, Walzl G, Ehlers MM, Kock MM, Zumla A, et al. A broad profile of co-dominant epitopes shapes the peripheral Mycobac-terium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis. PLo S One (2013) 8:e58309. doi:10.1371/ journal.pone.0058309
30. Commandeur S, van Meijgaarden KE, Prins C, Pichugin AV, Dijkman K, van den Eeden SJ, et al. An unbiased genome-wide Mycobacterium tubercu-losis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J Immunol (2013) 190:1659-71. doi:10.4049/jimmunol.1201593
31. Cho S, Mehra V, Thoma-Uszynski S, Stenger S, Serbina N, Mazzaccaro RJ, et al. Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proc Natl Acad Sci U S A (2000) 97:12210-5. doi:10.1073/pnas. 210391497
32. Hammond AS, Klein MR, Corrah T, Fox A, Jaye A, Mc Adam KP, et al. Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 T cell epitopes.Clin Exp Immunol (2005) 140:109-16. doi:10.1111/j.1365-2249.2005. 02751.x
33. Mc Murry JA, Kimball S, Lee JH, Rivera D, Martin W, Weiner DB, et al. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med (2007) 7:351-68. doi:10.2174/156652407780831584
34. Cain JA, Solis N, Cordwell SJ. Beyond gene expression: the impact of protein post-translational modifications in bacteria. J Proteomics (2014) 97:265-86. doi:10.1016/j.jprot.2013.08.012
35. Olsen JV, Mann M. Status of large-scale analysis of post-translational mod-ifications by mass spectrometry. Mol Cell Proteomics (2013) 12:3444-52. doi:10.1074/mcp.O113.034181
36. Jensen ON. Modification-specific proteomics: characterization of post-translationalmodifications bymass spectrometry. Curr Opin Chem Biol (2004) 8:33-41. doi:10.1016/j.cbpa.2003.12.009
37. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol (2003) 21:255-61. doi:10.1038/nbt0303-255
38. Bell C, Smith GT, Sweredoski MJ, Hess S. Characterization of the Mycobac-terium tuberculosis proteome by liquid chromatography mass spectrometry-based proteomics techniques: a comprehensive resource for tuberculosis research. J Proteome Res (2012) 11:119-30. doi:10.1021/pr2007939
39. Vander Ven BC, Harder JD, Crick DC, Belisle JT. Export-mediated assembly of mycobacterial glycoproteins parallels eukaryotic pathways. Science (2005) 309:941-3. doi:10.1126/science.1114347
40. Espitia C, Mancilla R. Identification, isolation and partial characterization of Mycobacterium tuberculosis glycoprotein antigens. Clin Exp Immunol (1989) 77:378-83.
41. Dobos KM, Khoo KH, Swiderek KM, Brennan PJ, Belisle JT. Definition of the full extent of glycosylation of the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. J Bacteriol (1996) 178:2498-506.
42. Herrmann JL, O'Gaora P, Gallagher A, Thole JE, Young DB. Bacterial glycopro-teins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis. EMBO J (1996) 15:3547-54.
43. Herrmann JL, Delahay R, Gallagher A, Robertson B, Young D. Analysis of post-translationalmodification ofmycobacterial proteins using a cassette expression system. FEBS Lett (2000) 473:358-62. doi:10.1016/S0014-5793(00)01553-2
44. Sartain MJ, Belisle JT. N-terminal clustering of the O-glycosylation sites in the Mycobacterium tuberculosis lipoprotein Sod C. Glycobiology (2009) 19:38-51. doi:10.1093/glycob/cwn102
45. Smith GT, Sweredoski MJ, Hess S. O-linked glycosylation sites profiling in Mycobacterium tuberculosis culture filtrate proteins. J Proteomics (2014) 97:296-306. doi:10.1016/j.jprot.2013.05.011
46. Kusebauch U, Ortega C, Ollodart A, Rogers RS, Sherman DR, Moritz RL, et al. Mycobacterium tuberculosis supports protein tyrosine phosphorylation. Proc Natl Acad Sci U S A (2014) 111:9265-70. doi:10.1073/pnas.1323894111
47. Prisic S, Dankwa S, Schwartz D, Chou MF, Locasale JW, Kang CM, et al. Exten-sive phosphorylation with overlapping specificity by Mycobacterium tuber-culosis serine/threonine protein kinases. Proc Natl Acad Sci U S A (2010) 107:7521-6. doi:10.1073/pnas.0913482107
48. Pethe K, Bifani P, Drobecq H, Sergheraert C, Debrie AS, Locht C, et al.Mycobac-terial heparin-binding hemagglutinin and laminin-binding protein share anti-genic methyllysines that confer resistance to proteolysis. Proc Natl Acad Sci U S A (2002) 99:10759-64. doi:10.1073/pnas.162246899
49. Okkels LM, Muller EC, Schmid M, Rosenkrands I, Kaufmann SH, Andersen P, et al. CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. Proteomics (2004) 4:2954-60. doi:10.1002/pmic.200400906
50. Sutcliffe IC, Harrington DJ. Lipoproteins of Mycobacterium tuberculosis: an abundant and functionally diverse class of cell envelope components. FEMS Microbiol Rev (2004) 28:645-59. doi:10.1016/j.femsre.2004.06.002
51. Okuda S, Tokuda H. Lipoprotein sorting in bacteria.Annu Rev Microbiol (2011) 65:239-59. doi:10.1146/annurev-micro-090110-102859
52. Brulle JK, Tschumi A, Sander P. Lipoproteins of slow-growing Mycobacteria carry three fatty acids and are N-acylated by apolipoprotein N-acyltransferase BCG_2070c. BMC Microbiol (2013) 13:223. doi:10.1186/1471-2180-13-223
53. Sanchez A, Espinosa P, Esparza MA, Colon M, Bernal G, Mancilla R. Mycobac-terium tuberculosis 38-kDa lipoprotein is apoptogenic for human monocyte-derived macrophages. Scand J Immunol (2009) 69:20-8. doi:10.1111/j.1365-3083.2008.02193.x
54. Sanchez A, Espinosa P, Garcia T, Mancilla R. The 19 kDa Mycobacterium tuberculosis lipoprotein (Lpq H) induces macrophage apoptosis through extrinsic and intrinsic pathways: a role for the mitochondrial apoptosis-inducing factor. Clin Dev Immunol (2012) 2012:950503. doi:10.1155/2012/ 950503
55. Lancioni CL, Li Q, Thomas JJ, Ding X, Thiel B, Drage MG, et al. Mycobac-terium tuberculosis lipoproteins directly regulate human memory CD4(+) T cell activation via Toll-like receptors 1 and 2. Infect Immun (2011) 79:663-73. doi:10.1128/IAI.00806-10
56. Striebel F, Imkamp F, Sutter M, Steiner M, Mamedov A, Weber-Ban E. Bac-terial ubiquitin-like modifier Pup is deamidated and conjugated to substrates by distinct but homologous enzymes. Nat Struct Mol Biol (2009) 16:647-51. doi:10.1038/nsmb.1597
57. Chun T, Serbina NV, Nolt D, Wang B, Chiu NM, Flynn JL, et al. Induction of M3-restricted cytotoxic T lymphocyte responses by N-formylated pep-tides derived fromMycobacteriumtuberculosis. J Exp Med (2001) 193:1213-20. doi:10.1084/jem.193.10.1213
58. Doi T, Yamada H, Yajima T, Wajjwalku W, Hara T, Yoshikai Y. H2-M3-restricted CD8+ T cells induced by peptide-pulsed dendritic cells confer pro-tection against Mycobacterium tuberculosis. J Immunol (2007) 178:3806-13. doi:10.4049/jimmunol.178.6.3806
59. Pearce MJ, Mintseris J, Ferreyra J, Gygi SP, Darwin KH. Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis. Science (2008) 322:1104-7. doi:10.1126/science.1163885
60. Barandun J, Delley CL, Weber-Ban E. The pupylation pathway and its role in mycobacteria. BMC Biol (2012) 10:95. doi:10.1186/1741-7007-10-95
61. Cerda-Maira FA, Pearce MJ, Fuortes M, Bishai WR, Hubbard SR, Darwin KH. Molecular analysis of the prokaryotic ubiquitin-like protein (Pup) conjuga-tion pathway inMycobacteriumtuberculosis.Mol Microbiol (2010) 77:1123-35. doi:10.1111/j.1365-2958.2010.07276.x
62. Burns KE, Pearce MJ, Darwin KH. Prokaryotic ubiquitin-like protein provides a two-part degron toMycobacteriumproteasome substrates. J Bacteriol (2010) 192:2933-5. doi:10.1128/JB.01639-09
63. Tung CW. Pup DB: a database of pupylated proteins. BMC Bioinformatics (2012) 13:40. doi:10.1186/1471-2105-13-40
64. Burns KE, Cerda-Maira FA, Wang T, Li H, Bishai WR, Darwin KH. "Depupy-lation" of prokaryotic ubiquitin-like protein from mycobacterial proteasome substrates. Mol Cell (2010) 39:821-7. doi:10.1016/j.molcel.2010.07.019
65. Power PM, Jennings MP. The genetics of glycosylation in Gram-negative bac-teria. FEMS Microbiol Lett (2003) 218:211-22. doi:10.1111/j.1574-6968.2003. tb11520.x
66. Iwashkiw JA, Vozza NF, Kinsella RL, Feldman MF. Pour some sugar on it: the expanding world of bacterial protein O-linked glycosylation. Mol Microbiol (2013) 89:14-28. doi:10.1111/mmi.12265
67. Nothaft H, Szymanski CM. Protein glycosylation in bacteria: sweeter than ever. Nat Rev Microbiol (2010) 8:765-78. doi:10.1038/nrmicro2383
68. Espitia C, Servin-Gonzalez L, Mancilla R. New insights into protein O-mannosylation in actinomycetes. Mol Biosyst (2010) 6:775-81. doi:10.1039/ b916394h
69. Liu CF, Tonini L, Malaga W, Beau M, Stella A, Bouyssie D, et al. Bacterial protein-O-mannosylating enzyme is crucial for virulence of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2013) 110:6560-5. doi:10.1073/pnas. 1219704110
70. Horn C, Namane A, Pescher P, Riviere M, Romain F, Puzo G, et al. Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuber-culosis to stimulate T lymphocyte responses related to changes in their man-nosylation pattern. J Biol Chem (1999) 274:32023-30. doi:10.1074/jbc.274.45. 32023
71. Ge Y, El-Naggar M, Sze SK, Oh HB, Begley TP, Mc Lafferty FW, et al. Top down characterization of secreted proteins fromMycobacterium tuberculosis by elec-tron capture dissociation mass spectrometry. J Am Soc Mass Spectrom (2003) 14:253-61. doi:10.1016/S1044-0305(02)00913-3
72. Steingart KR, Dendukuri N, Henry M, Schiller I, Nahid P, Hopewell PC, et al. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol (2009) 16:260-76. doi:10.1128/CVI. 00355-08
73. Diaz-Silvestre H, Espinosa-Cueto P, Sanchez-Gonzalez A, Esparza-Ceron MA, Pereira-Suarez AL, Bernal-Fernandez G, et al. The 19-kDa antigen of Mycobac-teriumtuberculosis is amajor adhesin that binds themannose receptor of THP-1 monocytic cells and promotes phagocytosis of mycobacteria. Microb Pathog (2005) 39:97-107. doi:10.1016/j.micpath.2005.06.002
74. Ragas A, Roussel L, Puzo G, Riviere M. The Mycobacterium tuberculosis cell-surface glycoprotein apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A. J Biol Chem (2007) 282:5133-42. doi:10.1074/jbc.M610183200
75. Pitarque S, Herrmann JL, Duteyrat JL, Jackson M, Stewart GR, Lecointe F, et al. Deciphering the molecular bases of Mycobacterium tuberculosis binding to the lectinDC-SIGNreveals an underestimated complexity. Biochem J (2005) 392:615-24. doi:10.1042/BJ20050709
76. Rezwan M, Grau T, Tschumi A, Sander P. Lipoprotein synthesis in mycobacte-ria. Microbiology (2007) 153:652-8. doi:10.1099/mic.0.2006/000216-0
77. Tschumi A, Grau T, Albrecht D, Rezwan M, Antelmann H, Sander P. Func-tional analyses ofmycobacterial lipoprotein diacylglyceryl transferase and com-parative secretome analysis of a mycobacterial lgt mutant. J Bacteriol (2012) 194:3938-49. doi:10.1128/JB.00127-12
78. Rampini SK, Selchow P, Keller C, Ehlers S, Bottger EC, Sander P. Lsp A inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest. Microbiology (2008) 154:2991-3001. doi:10.1099/mic.0.2008/018895-0
79. Sander P, Rezwan M, Walker B, Rampini SK, Kroppenstedt RM, Ehlers S, et al. Lipoprotein processing is required for virulence ofMycobacteriumtuberculosis. Mol Microbiol (2004) 52:1543-52. doi:10.1111/j.1365-2958.2004.04041.x
80. Zahringer U, Lindner B, Inamura S, Heine H, Alexander C. TLR2 -promis-cuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology (2008) 213:205-24. doi:10.1016/j.imbio. 2008.02.005
81. Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT, et al. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J Immunol (2001) 167:910-8. doi:10.4049/jimmunol.167.2.910
82. Lopez M, Sly LM, Luu Y, Young D, Cooper H, Reiner NE. The 19-kDa Mycobac-terium tuberculosis protein induces macrophage apoptosis through Toll-like receptor-2. J Immunol (2003) 170:2409-16. doi:10.4049/jimmunol.170.5.2409
83. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell (2007) 130:1071-82. doi:10.1016/j.cell.2007.09.008
84. Mir SA, Sharma S. Immunotherapeutic potential of N-formylated pep-tides of ESAT-6 and glutamine synthetase in experimental tuberculosis. Int Immunopharmacol (2014) 18:298-303. doi:10.1016/j.intimp.2013.09.010
85. Vetting MW, Errey JC, Blanchard JS. Rv0802c from Mycobacterium tubercu-losis: the first structure of a succinyltransferase with the GNAT fold. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 64:978-85. doi:10.1107/ S1744309108031679
86. Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dis-semination. Nature (2001) 412:190-4. doi:10.1038/35084083
87. Lebrun P, Raze D, Fritzinger B, Wieruszeski JM, Biet F, Dose A, et al.Differential contribution of the repeats to heparin binding of HBHA, a major adhesin of Mycobacterium tuberculosis. PLo S One (2012) 7:e32421. doi:10.1371/journal. pone.0032421
88. Menozzi FD, Rouse JH, Alavi M, Laude-Sharp M, Muller J, Bischoff R, et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med (1996) 184:993-1001. doi:10.1084/jem.184.3.993
89. Sohn H, Kim JS, Shin SJ, Kim K, Won CJ, Kim WS, et al. Targeting of Mycobacterium tuberculosis heparin-binding hemagglutinin to mitochondria in macrophages. PLo S Pathog (2011) 7:e1002435. doi:10.1371/journal.ppat. 1002435
90. Lefrancois LH, Bodier CC, Lecher S, Gilbert FB, Cochard T, Harichaux G, et al. Purification of native HBHA from Mycobacterium avium subsp. paratubercu-losis. BMC Res Notes (2013) 6:55. doi:10.1186/1756-0500-6-55
91. Romain F, Horn C, Pescher P, Namane A, Riviere M, Puzo G, et al. Deglycosy-lation of the 45/47-kilodalton antigen complex of Mycobacterium tuberculosis decreases its capacity to elicit in vivo or in vitro cellular immune responses. Infect Immun (1999) 67:5567-72.
92. Nandakumar S, Kannanganat S, Dobos KM, Lucas M, Spencer JS, Fang S, et al. O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection. PLo S Pathog (2013) 9:e1003705. doi:10.1371/journal.ppat.1003705
93. Kumar P, Amara RR, Challu VK, Chadda VK, Satchidanandam V. The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pigmodel. Infect Immun (2003) 71:1929-37 doi:10.1128/IAI.71.4.1929-1937.2003
94. Sable SB, Cheruvu M, Nandakumar S, Sharma S, Bandyopadhyay K, Kella KL, et al. Cellular immune responses to nine Mycobacterium tuberculosis vac cine candidates following intranasal vaccination. PLo S One (2011) 6:e22718 doi:10.1371/journal.pone.0022718
95. Temmerman S, Pethe K, Parra M, Alonso S, Rouanet C, Pickett T et al. Methylation-dependent T cell immunity to Mycobacterium tuberculo sis heparin-binding hemagglutinin. Nat Med (2004) 10:935-41. doi:10.1038 nm1090
96. Parra M, Pickett T, Delogu G, Dheenadhayalan V, Debrie AS, Locht C, et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen i the mouse aerosol challenge model of tuberculosis. Infect Immun (2004 72:6799-805. doi:10.1128/IAI.72.12.6799-6805.2004
97. Masungi C, Temmerman S, Van Vooren JP, Drowart A, Pethe K, Menozz FD, et al. Differential T and B cell responses against Mycobacterium tubercu losis heparin-binding hemagglutinin adhesin in infected healthy individual and patients with tuberculosis. J Infect Dis (2002) 185:513-20. doi:10.1086 338833
98. Loxton AG, Black GF, Stanley K, Walzl G. Heparin-binding hemagglutini induces IFN-gamma(+) IL-2(+) IL-17(+)multifunctional CD4(+) T cells dur ing latent but not active tuberculosis disease. Clin Vaccine Immunol (2012 19:746-51. doi:10.1128/CVI.00047-12
99. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years late Lancet Infect Dis (2011) 11:633-40. doi:10.1016/S1473-3099(11)70146-3
100. Smith SG, Lecher S, Blitz R, Locht C, Dockrell HM. Broad heparin-bindin haemagglutinin-specific cytokine and chemokine response in infants follow ingMycobacterium bovis BCG vaccination. Eur J Immunol (2012) 42:2511-22 doi:10.1002/eji.201142297
101. Aagaard CS, Hoang TT, Vingsbo-Lundberg C, Dietrich J, Andersen P. Qual ity and vaccine efficacy of CD4+ T cell responses directed to dominant an subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immuno (2009) 183:2659-68. doi:10.4049/jimmunol.0900947
102. Woodworth JS, Aagaard CS, Hansen PR, Cassidy JP, Agger EM, Andersen P Protective CD4 T cells targeting cryptic epitopes of Mycobacteriumtuberculosi resist infection-driven terminal differentiation. J Immunol (2014) 192:3247-58. doi:10.4049/jimmunol.1300283
103. van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-live Mycobacterium tuberculosis specific T cell responses in volunteers with pre vious BCG vaccination or tuberculosis infection. Vaccine (2011) 29:2100-9 doi:10.1016/j.vaccine.2010.12.135
104. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, Schultze JL, Finn O O-Linked glycans control glycoprotein processing by antigen-presenting cells a biochemical approach to the molecular aspects of MUC1 processing by den dritic cells. Eur J Immunol (2003) 33:3242-54. doi:10.1002/eji.200324189
105. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antige processing and presentation. Nat Rev Immunol (2008) 8:607-18. doi:10.1038 nri2368
106. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, et a Characterization of peptides bound to the class IMHCmolecule HLA-A2.1 b mass spectrometry. Science (1992) 255:1261-3. doi:10.1126/science.1546328
107. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF et al. HLA-A2.1-associated peptides from a mutant cell line: a second path way of antigen presentation. Science (1992) 255:1264-6. doi:10.1126/science 1546329
108. Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, et a The human leukocyte antigen-presented ligandome of B lymphocytes.Mol Ce Proteomics (2013) 12:1829-43. doi:10.1074/mcp.M112.024810
109. Mommen GP, Frese CK, Meiring HD, van Gaans-van den Brink J, de Jon AP, van Els CA, et al. Expanding the detectable HLA peptide repertoire usin electron-transfer/higher-energy collision dissociation (EThc D). Proc Natl Aca Sci U S A (2014) 111:4507-12. doi:10.1073/pnas.1321458111
110. Rammensee HG. Chemistry of peptides associated withMHC class I and clas II molecules. Curr Opin Immunol (1995) 7:85-96. doi:10.1016/0952-7915(95 80033-6
111. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs first listing. Immunogenetics (1995) 41:178-228. doi:10.1007/BF00172063
112. Lampen MH, Hassan C, Sluijter M, Geluk A, Dijkman K, Tjon JM, et al. Alter-native peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol Immunol (2013) 53:126-31. doi:10.1016/j.molimm. 2012.07.009
113. van Els CA, Herberts CA, van der Heeft E, Poelen MC, van Gaans-van den Brink JA, van der Kooi A, et al. A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur J Immunol (2000) 30:1172-81. doi:10.1002/(SICI)1521-4141(200004)30:4<1172::AID-IMMU1172>3.0.CO;2-J
114. Hillen N, Stevanovic S. Contribution of mass spectrometry-based pro-teomics to immunology. Expert Rev Proteomics (2006) 3:653-64. doi:10.1586/ 14789450.3.6.653
115. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, et al. An HLA-A2-restricted tyrosinase antigen onmelanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med (1996) 183:527-34. doi:10.1084/jem.183.2.527
116. Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med (2011) 208:2625-32. doi:10.1084/jem.20110640
117. Pierce RA, Field ED, denHaan JM, Caldwell JA, White FM, Marto JA, et al. Cut-ting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identi-fied by a novel mass spectrometric technique. J Immunol (1999) 163:6360-4.
118. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature (2004) 427:252-6. doi:10.1038/nature02240
119. Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, et al. An antigenic peptide produced by peptide splicing in the proteasome. Science (2004) 304:587-90. doi:10.1126/science.1095522
120. Engelhard VH. Creating new peptide antigens by slicing and splicing proteins. Nat Immunol (2004) 5:128-9. doi:10.1038/ni0204-128
121. Bullock TN, Patterson AE, Franlin LL, Notidis E, Eisenlohr LC. Initiation codon scanthrough versus termination codon readthrough demonstrates strong potential for major histocompatibility complex class I-restricted cryptic epitope expression. J Exp Med (1997) 186:1051-8. doi:10.1084/jem. 186.7.1051
122. Malarkannan S, Horng T, Shih PP, Schwab S, Shastri N. Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism. Immunity (1999) 10:681-90. doi:10.1016/S1074-7613(00)80067-9
123. Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, et al. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res (2003) 63:6506-15.
124. Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, et al. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrome-try. Eur J Immunol (2004) 34:3644-51. doi:10.1002/eji.200425510
125. Lemmel C, Weik S, Eberle U, Dengjel J, Kratt T, Becker HD, et al. Differen-tial quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol (2004) 22:450-4. doi:10.1038/nbt947
126. Meiring HD, Kuipers B, vanGaans-van den Brink JA, Poelen MC, Timmermans H, Baart G, et al. Mass tag-assisted identification of naturally processed HLA class II-presentedmeningococcal peptides recognized byCD4+T lymphocytes. J Immunol (2005) 174:5636-43. doi:10.4049/jimmunol.174.9.5636
127. Meiring HD, Soethout EC, Poelen MC, Mooibroek D, Hoogerbrugge R, Tim-mermans H, et al. Stable isotope tagging of epitopes: a highly selective strategy for the identification of major histocompatibility complex class I-associated peptides induced upon viral infection. Mol Cell Proteomics (2006) 5:902-13. doi:10.1074/mcp.T500014-MCP200
128. Soethout EC, Meiring HD, de Jong AP, van Els CA. Identifying the epitope-specific T cell response to virus infections. Vaccine (2007) 25:3200-3. doi:10. 1016/j.vaccine.2007.01.029
129. Stenger RM, Meiring HD, Kuipers B, Poelen M, van Gaans-van den Brink JA, Boog CJ, et al. Bordetella pertussis proteins dominating the MHC Class II-presented epitope repertoire in human monocyte derived dendritic cells. Clin Vaccine Immunol (2014) 21:641-50. doi:10.1128/CVI.00665-13
130. Flyer DC, Ramakrishna V, Miller C, Myers H, Mc Daniel M, Root K, et al. Iden-tification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product. Infect Immun (2002) 70:2926-32. doi:10.1128/IAI.70.6.2926-2932.2002
131. Harding CV, Boom WH. Regulation of antigen presentation byMycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol (2010) 8:296-307. doi:10.1038/nrmicro2321
132. Hava DL, van derWel N, Cohen N, Dascher CC, Houben D, Leon L, et al. Eva-sion of peptide, but not lipid antigen presentation, through pathogen-induced dendritic cell maturation. Proc Natl Acad Sci U S A (2008) 105:11281-6. doi:10.1073/pnas.0804681105